Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Inv. presentation
ARS Pharmaceuticals, Inc. (SBTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates ARS continues engagement with U.S. FDA on final labeling and post-marketing commitments for the neffy® new drug application; PDUFA target action date set for September 19, 2023 Ended second quarter with $252.2 million in cash, cash equivalents and short-term investments; well-capitalized to support anticipated launch of neffy in the U.S. and an expected operating runway of at least three years SAN DIEGO – August 10, 2023 -ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the second quarter of 2023. &#x2..."
08/07/2023 4 Shawver Laura (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Sold 26,107 shares @ $7.0103, valued at $183k
Sold 18,897 shares @ $7.0631, valued at $133.5k
Exercised 26,017 options to buy @ $1.27, valued at $33k
Exercised 18,897 options to buy @ $1.27, valued at $24k
08/03/2023 4 Shawver Laura (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Sold 18,715 shares @ $7.1908, valued at $134.6k
Sold 36,281 shares @ $7.0909, valued at $257.3k
Exercised 18,715 options to buy @ $1.27, valued at $23.8k
Exercised 36,281 options to buy @ $1.27, valued at $46.1k
08/01/2023 144 Form 144 - Report of proposed sale of securities:
07/07/2023 4 Shawver Laura (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Sold 8,858 shares @ $6.364, valued at $56.4k
Exercised 8,858 options to buy @ $1.27, valued at $11.2k
07/06/2023 4 Shawver Laura (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Sold 26,520 shares @ $6.725, valued at $178.3k
Sold 31,112 shares @ $6.414, valued at $199.6k
Sold 33,510 shares @ $6.343, valued at $212.6k
Exercised 26,520 options to buy @ $1.27, valued at $33.7k
Exercised 31,112 options to buy @ $1.27, valued at $39.5k
Exercised 33,510 options to buy @ $1.27, valued at $42.6k
07/03/2023 144 Form 144 - Report of proposed sale of securities:
06/28/2023 4 Dadoo Rajeev (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Granted 40,000 options to buy @ $6.5, valued at $260k
06/28/2023 4 RA CAPITAL MANAGEMENT, L.P. (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Granted 40,000 options to buy @ $6.5, valued at $260k
06/28/2023 4 Kelly Michael (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Granted 40,000 options to buy @ $6.5, valued at $260k
06/28/2023 4 Shah Pratik (10% Owner) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Granted 40,000 options to buy @ $6.5, valued at $260k
06/28/2023 4 Thompson Peter A. (10% Owner) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Granted 40,000 options to buy @ $6.5, valued at $260k
06/28/2023 4 Shawver Laura (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Granted 40,000 options to buy @ $6.5, valued at $260k
06/28/2023 4 SAUNDERS BRENT L (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Granted 40,000 options to buy @ $6.5, valued at $260k
06/28/2023 4 SCHNEIDER PHILLIP M (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Granted 40,000 options to buy @ $6.5, valued at $260k
06/28/2023 4 Islam Saqib (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Granted 40,000 options to buy @ $6.5, valued at $260k
06/28/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/02/2023 4 Shawver Laura (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Sold 73,059 shares @ $6.8, valued at $496.8k
Sold 26,941 shares @ $6.95, valued at $187.2k
Exercised 73,059 options to buy @ $1.27, valued at $92.8k
Exercised 26,941 options to buy @ $1.27, valued at $34.2k
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/16/2023 8-K Investor presentation
Docs: "Corporate Presentation"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® for the Treatment of Allergic Reactions , Including Anaphylaxis New Drug and Marketing Authorization Applications for neffy Under Review with FDA and EMA, Respectively; FDA PDUFA Target Action Date Anticipated mid-2023 $264.5 Million in Cash, Cash Equivalents and Short-term Investments to Support Operating Runway for the Next Three Years, Including the Planned Commercialization of neffy in the United States SAN DIEGO – May 15, 2023 -ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead t..."
05/10/2023 4 Shawver Laura (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.
Txns: Sold 43,896 shares @ $4.58, valued at $201k
Sold 57,100 shares @ $6.16, valued at $351.7k
Sold 42,900 shares @ $5.31, valued at $227.8k
Exercised 57,100 options to buy @ $1.27, valued at $72.5k
Exercised 42,900 options to buy @ $1.27, valued at $54.5k
05/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Company comments to FDA Briefing Document",
"Company comments to FDA Briefing Document"
05/08/2023 144 Form 144 - Report of proposed sale of securities:
05/04/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA and EMA; FDA PDUFA Target Action Date Anticipated in Mid-2023 Strong Financial Position with $274.4 Million in Cash, Cash Equivalents and Short-term Investments to Support Operating Runway for the Next Three Years SAN DIEGO – March 23, 2023 - ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today highlighted recent progress and reported fourth quarter and full year 2022 financial results. “This is an incredibly exciting ti..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy